1. Pfizer's stock has likely bottomed and shows strong technical and fundamental indicators; 2. The company's promising pipeline includes weight-loss treatments and AI-driven drug discovery; 3. The Seagen acquisition enhances Pfizer's cancer treatment portfolio, positioning it well in a high-demand sector.